Effects of Radiotherapy and Chemotherapy on Lung Function in Patients with Non-small-cell Lung Cancer
Overview
Authors
Affiliations
Purpose: To evaluate the effects of chemoradiation on objective tests of pulmonary function.
Materials And Methods: One hundred lung cancer patients treated in five protocols between 1992 and 2000 with combinations of thoracic radiotherapy (RT) and chemotherapy were evaluated with pre- and post-RT pulmonary function tests. The pulmonary function tests were analyzed for changes in measures of obstruction (forced expiratory volume in 1 s per unit of vital capacity [FEV(1)/VC]), restriction (total lung capacity [TLC]), and diffusing capacity (diffusing capacity for carbon monoxide [DLCO]). The use and timing of chemotherapy and RT, as well as patient, tumor, and treatment factors, were evaluated using univariate and multivariate analyses.
Results: No treatment or patient factors were significantly associated with changes in FEV(1)/VC. Chemotherapy with RT, compared with RT alone, was associated with a lower post-RT TLC (92% vs. 107%, p = 0.002). Nodal status (N2-N3 vs. N1), tumor location (central vs. peripheral), use of >/=6 treatment fields, and tumor volume >/=100 cm(3) were also associated with a significantly lower post-RT TLC. On univariate analysis, the use of any chemotherapy (p = 0.029) and the use of concurrent vs. sequential chemotherapy (p = 0.028) were predictive of a lower post-RT DLCO. Patient age >/=60 years, nodal status (N2-N3 vs. N0-N1), tumor volume >/=100 cm(3), tumor location (central vs. peripheral), and use of >/=6 treatment fields were also associated with a significantly lower post-RT DLCO. The fractional volume of irradiated normal lung correlated with the decrease in DLCO (p <0.001), with a 1.3% DLCO decline for each 1% of total lung volume that received >20 Gy.
Conclusions: The addition of chemotherapy to RT significantly exacerbates the post-RT decrease in TLC and DLCO. The greatest decrease in DLCO occurs in patients treated with concurrent chemoradiation.
Lim J, Kang H, Yeo C, Kim J, Kim S, Kim J Ther Adv Med Oncol. 2024; 16:17588359241281480.
PMID: 39371616 PMC: 11450872. DOI: 10.1177/17588359241281480.
Ghassemi N, Castillo R, Castillo E, Jones B, Miften M, Kavanagh B Radiother Oncol. 2023; 187:109821.
PMID: 37516361 PMC: 10529225. DOI: 10.1016/j.radonc.2023.109821.
Lee T, Kang B, Kim H, Wu H, Lee J Cancer Res Treat. 2023; 55(3):865-874.
PMID: 36701844 PMC: 10372601. DOI: 10.4143/crt.2022.1538.
Radiation-induced lung injury - what do we know in the era of modern radiotherapy?.
Konkol M, Sniatala P, Milecki P Rep Pract Oncol Radiother. 2022; 27(3):552-565.
PMID: 36186693 PMC: 9518776. DOI: 10.5603/RPOR.a2022.0046.
Connolly J, Fiasconaro M, Tan K, Cirelli Jr M, Jones G, Caso R J Thorac Cardiovasc Surg. 2022; 164(2):389-397.e7.
PMID: 35086669 PMC: 9218003. DOI: 10.1016/j.jtcvs.2021.12.030.